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Mutations in nuclear genes involved inmitochondrial DNA (mtDNA)maintenance cause awide range of clinical
phenotypes associated with the secondary accumulation of multiple mtDNA deletions in affected tissues.
The majority of families with autosomal dominant progressive external ophthalmoplegia (PEO) harbour muta-
tions in genes encoding one of three well-characterized proteinsçpolc, Twinkle or Ant 1. Here we show that
a heterozygous mis-sense mutation in OPA1 leads to multiple mtDNA deletions in skeletal muscle and a
mosaic defect of cytochrome c oxidase (COX).The disorder presented with visual failure and optic atrophy in
childhood, followed by PEO, ataxia, deafness and a sensory-motor neuropathy in adult life. COX-deficient
skeletal muscle fibres contained supra-threshold levels of multiple mtDNA deletions, and genetic linkage,
sequencing and expression analysis excluded POLG1, PEO1 and SLC25A4, the gene encoding Ant 1, as the cause.
This demonstrates the importance of OPA1 in mtDNAmaintenance, and implicates OPA1 in diseases associated
with secondary defects of mtDNA.
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Introduction
The synthesis of ATP by mitochondrial oxidative phosphor-
ylation is dependent upon the coordinated expression and
interaction of both nuclear and mitochondrial-encoded gene
products. Mutations in nuclear genes involved in mitochon-
drial DNA (mtDNA) maintenance are increasingly associated
with a variety of clinical phenotypes ranging from severe
encephalopathy and liver failure in childhood to late-onset
progressive external ophthalmoplegia (PEO), ataxia, myop-
athy and parkinsonism (Zeviani and Di Donato, 2004;
Schapira, 2006). These include recessive mutations in
POLG1, encoding the catalytic alpha-subunit of DNA
polymerase g, polg or POLGA (Van Goethem et al., 2001);
TK2, encoding thymine kinase (Saada et al., 2001); DGUOK,
encoding dexyguanosine kinase (Mandel et al., 2001),
SUCLA2 (Elpeleg et al., 2005); MPV17 (Spinazzola et al.,
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2006); and RRM2B (Bourdon et al., 2007), which lead to a
mtDNA depletion. Alternatively, dominant mutations in
POLG1, (Van Goethem et al., 2001); POLG2, encoding the
accessory beta-subunit of polg, POLGB (Longley et al., 2006);
PEO1, previously known as C10Orf2, encoding the mitochon-
drial helicase Twinkle (Spelbrink et al., 2001); SLC25A4,
encoding adenine nucleotide translocator 1, Ant 1 (Kaukonen
et al., 2000); and recessive mutations in TP, encoding
thymidine phosphorylase (Nishino et al., 1999), which lead
to a secondary accumulation of multiple deletions in mtDNA
in affected tissues and an associated respiratory chain defect.
The majority of patients with an apparent autosomal
dominant (ad) family history of mitochondrial disease and
demonstrable multiple mtDNA deletions in muscle harbour
a mutation in POLG1, PEO1 or SLC25A4 (Lamantea et al.,
2002), but in many cases it is not possible to reach a
molecular diagnosis (Hudson et al., 2006). Investigating
these pedigrees can be revealing, identifying novel disease
genes leading to the detailed dissection of critical biochem-
ical pathways which maintain mtDNA and cause human
disease (Longley et al., 2006).
Mutations in nuclear genes that maintain mtDNA cause a
diverse spectrum of overlapping phenotypes. Visual failure
and optic atrophy have been described, but rarely dominate
the phenotype (Hakonen et al., 2005; Horvath et al., 2006). By
contrast, visual failure may be themajor phenotype in patients
with mutations in autosomal dominant optic atrophy
(ad-OA). Mutations in OPA1, which codes for a dynamin-
related guanosine triphosphatase (GTPase), are the most
common cause of ad-OA (Alexander et al., 2000; Delettre
et al., 2000). Other loci have been implicated in X-linked optic
atrophy (OPA2; Katz et al., 2006), autosomal recessive (ar)
optic atrophy with cataract (OPA3; Anikster et al., 2001),
dominant optic atrophy with or without deafness (OPA4;
Kerrison et al., 1999) and OPA5 (Barbet et al., 2005) and early
onset ar-OA (OPA6)(Barbet et al., 2003). Additional neuro-
logical features have been described in these disorders,
including deafness (Amati-Bonneau et al., 2005) or ophthal-
moplegia (Payne et al., 2004) in patients withOPA1mutations,
and spasticity, extrapyramidal dysfunction and cognitive
impairment in OPA3 (Costeff’s syndrome, 3-methylglutaconic
aciduria type III)(Costeff and Elpeleg, 1995). Here we describe a
family with a different phenotype, presenting with profound
visual failure and optic atrophy developing in childhood
followed by PEO, ataxia and deafness in later life. The
biochemical and molecular characterization of multiple
family members revealed multiple deletions of mtDNA in
skeletal muscle and a heterozygous mutation of OPA1,
implicating this gene in the maintenance of mtDNA and
multiple mtDNA deletions in the pathophysiology of ad-OA.
Materials and Methods
Patients
The family pedigree is shown in Fig. 1, with the index case (II:5)
highlighted (arrow).
II:2. A 60-year-old woman, who was registered blind at the age
of 6 years, presented at 50 years of age with progressive deafness
and a gait disturbance. The deafness had a history of 8 years. On
examination, she had an ataxic gait and Romberg test was
positive. She could just detect hand movements, had bilateral
ptosis, external ophthalmoplegia and bilateral optic atrophy but
no retinopathy. In the limbs, she had mild symmetric wasting of
quadriceps, and mild symmetric proximal muscle weakness (MRC
grade 4+). She was areflexic and had impaired sensation to all
modalities in a glove and stocking distribution. Clinical investiga-
tions revealed impaired glucose tolerance, an elevated serum
creatine kinase (493U/l, normal5190U/l). A fasting blood lactate
was 2.0mM/l. Nerve conduction studies revealed an axonal
sensorimotor neuropathy, with additional myopathic features on
electromyography. An electrocardiogram, echocardiogram, pul-
monary function tests and overnight oximetry were all within
normal limits. Brain MR imaging revealed a number of small
high-signal lesions in the frontal and temporal white matter on T2
imaging, thought to represent focal ischaemic lesions.
II:5. A 66-year-old woman had had visual impairment since
childhood and had attended a special school for the blind. She
presented with a further slowly progressive deterioration in her
visual acuity, a progressive gait disturbance of 20 years duration,
and a 5-year history of deteriorating hearing. Shortly after
presentation she developed acute paranoid delusions, low mood
and visual hallucinations which resolved spontaneously. On
examination, she was just able to perceive light and had bilateral
optic atrophy. There was a complete external ophthalmoplegia,
bilateral ptosis and bifacial weakness. Her gait was ataxic, tendon
reflexes depressed and plantar responses flexor. Clinical investiga-
tions revealed an elevated serum creatine kinase (417U/l, normal
5190U/l) with a normal fasting blood glucose and lactate.
An electrocardiogram showed left axis deviation but an
II:6II:1
IV:2
II:2 II:5
III:6III:1 III:2 III:4III:3
IV:1
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Fig. 1 Pedigree showing males (squares) and females (circles)
in a family with autosomal dominant external ophthalmoplegia
with optic atrophy and ataxia. Solid symbols = clinically affected
as described in the text.
330 Brain (2008), 131, 329^337 G. Hudson et al.
echocardiogram was normal. A chest X-ray and pulmonary
function tests were normal. An EEG revealed evidence of a mild
cortical disturbance. Brain MRI revealed mild cortical and
cerebellar atrophy, and prominent small-vessel ischaemic lesions
in the cerebral white matter bilaterally.
III:1 A 24-year-old man had normal early motor development
but developed a left hemiplegia following a road traffic accident at
5 years of age. His visual acuities progressively deteriorated
throughout childhood, and he developed mild ataxia in his early
20s. On examination, his visual acuity was reduced to counting
fingers in both eyes. He had a mild right-sided ptosis, bilateral
optic atrophy and a partial external ophthalmoplegia predomi-
nantly affecting down-gaze. He had bifacial muscle weakness, and
distal muscle wasting below the knees bilaterally, with bilateral pes
cavus. He had subtle spasticity in the left leg, with mild symmetric
proximal muscle weakness (MRC grade 4+) and profound
bilateral distal lower limb weakness (ankle dorsiflexion MRC
grade 2). His tendon reflexes were generally depressed, and absent
at both ankles. Plantar responses were extensor. There was a
marked gait ataxia with prominent positive Romberg sign. Clinical
investigations revealed an elevated serum creatine kinase (594U/l,
normal5190U/l), and a normal fasting blood glucose and lactate
(1.0mM/l). An electrocardiogram revealed a sinus bradycardia
and an echocardiogram was normal. Nerve conduction studies
and an electromyogram revealed an axonal sensorimotor neuro-
pathy. An electroencephalogram was normal. Overnight oximetry
was normal.
III:4 A 32-year-old woman was noted to have optic atrophy in
her second year of life. Her gait deteriorated from the age of 18
years, associated with mild proximal muscle weakness. At 23 years
of age she was diagnosed with irritable bowel syndrome. From 28
years of age she noted a slowly progressive hearing loss. On
examination, she had bilateral optic atrophy, pendular nystagmus
and mild gait ataxia. Routine blood tests revealed a normal
creatine kinase and a mildly elevated fasting blood lactate
(2.5mM/l). An electrocardiogram and echocardiogram were
normal. Respiratory function studies were normal. Peripheral
neurophysiological studies identified a mild sensorimotor neuro-
pathy with additional myopathic features on electromyography.
III:6 A 38-year-old man developed progressive visual failure in
childhood and was registered as partially sighted at age 11, and
registered blind at the age of 18 years. On examination he had an
ataxic gait, had bilateral optic atrophy and pendular nystagmus in
all positions of gaze. Up gaze and adduction was limited
symmetrically for both eyes, but there was no ptosis. Peripheral
tone, power and tendon reflexes were normal. Routine haemato-
logical and biochemical blood tests, including a serum creatine
kinase, were normal.
IV:1 Clinical data not available. He has never been brought to
medical attention with visual or neuromuscular symptoms.
IV:2 A 5-year-old girl was noted to have optic atrophy at 18
months of age, but otherwise had normal motor, verbal and social
development. On examination she was noted to have gaze-evoked
horizontal nystagmus on lateral gaze and bilateral optic atrophy,
and walked with a broad-based unsteady gait. The cranial nerve
and peripheral neurological examination was otherwise normal.
IV:3 A 6-year-old girl who was brought to medical attention at
1 year of age with a squint associated with progressive bilateral
visual failure and fine pendular nystagmus. Bilateral optic atrophy
was noted at 3 years of age. Her visual acuity deteriorated from
0.9 LogMAR (6/48 Snellen) bilaterally at 6 years. She was
otherwise asymptomatic.
Muscle histochemistry and biochemistry
Left quadriceps needle muscle biopsy was performed in three
patients (II:2, II:5 and III:1) under local anaesthetic. Histological
and histochemical analyses of mitochondrial enzyme activities
including a sequential reaction for cytochrome c oxidase (COX)
and succinate dehydrogenase (SDH) activities were performed on
10 mm-thick serial cross-sections of biopsy tissue according to
standard procedures. The activities of the individual respiratory
chain complexes were measured in post 600 gav skeletal muscle
supernatants and expressed relative to the activity of the matrix
marker enzyme citrate synthase (Taylor and Turnbull, 1997).
mtDNAmolecular genetic analysis
Total genomic DNA was extracted from skeletal muscle biopsies
and whole blood by standard procedures. Large-scale rearrange-
ments of the mitochondrial genome were screened by Southern
blot analysis of total DNA linearized with Pvu II and probed with
a PCR generated probe (nucleotides 15782–1289) that hybridizes
to the non-coding control region. A long-range PCR assay was
employed to amplify muscle mtDNA across the major arc, using a
pair of primers [L6249 (nucleotides 6249–6265) and H16215
(nucleotides 16225–16196)], which amplify a 9.9 kb product in
wild-type mtDNA. The level of deleted mtDNA in individual
COX-deficient and COX-positive staining muscle fibres isolated by
laser micro-dissection was determined by quantitative real-time
PCR as described (He et al., 2002). This assay uses primers and
fluorogenic probes to two different regions of the mitochondrial
genome, one which is rarely deleted in patients (MTND1) and
one which is located in the major mtDNA arc and is frequently
deleted (MTND4). PCR and fluorescence analyses were performed
using an ABI PRISM 7000 sequence detection system (Foster
City, CA).
The entire mitochondrial genome-coding region was amplified
using a series of 36 overlapping M13-tailed oligonucleotide primer
pairs. PCR products were purified (ExoSapIT, Amersham
Biosciences, Bucks, UK), sequenced using BigDye Terminator
cycle sequencing chemistries (v3.1, Applied Biosystems) on an
ABI3100 Genetic Analyser (Applied Biosystems) and directly
compared to the revised Cambridge Reference Sequence using
SeqScape software (Applied Biosystems).
To assess m.8839G4A heteroplasmy in tissues and individual
muscle fibres, a 250 bp fragment of mtDNA encompassing the
mutation site was amplified (30 cycles) using a forward primer
L8777 (nucleotides 8777–8794) and the reverse primer H9026
(nucleotides 9026–9008). Following the addition of 30 pmol of
each primer, 5 mCi [a-32P] dCTP (3000Ci/mmol) and 1 U of Taq
polymerase, PCR reactions were subjected to an additional cycle of
amplification. Labelled products were precipitated, digested at
37C with 7.5U Hae III (Roche Biochemicals). Restriction
fragments were separated through a 12% non-denaturing poly-
acrylamide gel, dried onto a support and exposed to a
PhosphorImager cassette. The level of mtDNA heteroplasmy was
quantified using ImageQuant software (Molecular Dynamics).
Two Hae III recognition sites in the wild-type product generates
fragments of 156, 63 and 31 bp; the m.8839G4A transition
results in the loss of a recognition site, yielding two products of
219 and 31 bp.
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Nuclear DNAmolecular genetic analysis
Both sense and anti-sense strands of the coding region and
intron–exon boundaries for POLG1, POLG2, PEO1 and SLC25A4
were sequenced using published primer sequences (Beckman–
Coulter Quickstart and CEQ 8000 fluorescent DNA analyzer)
(Hudson et al., 2006). The 30 coding exons and intron–exon
junctions of the OPA1 gene were sequenced using a set of 30
primer pairs (sequences available on request). Purified PCR
products were sequenced using a Ceq2000 DNA sequencer (CEQ
DTCS-Quick Start Kit, Beckman Coulter, Fullerton, CA, USA).
Genetic linkage analysis of the chromosomal regions flanking
POLG1, PEO1 and SLC25A4, was performed using selected
markers from the Applied Biosystems 10 cM screening set and
the 9 cM Cooperative Human Linkage Centre (CHLC) Weber
Human Screening set (Invitrogen, version 10aRG). The predicted
LOD score for the pedigree was obtained using Simlink v 2.52
based on a dominant inheritance model for a rare mutated allele
(100% penetrant, 0.001 frequency). Two- and multi-point linkage
analyses were performed using the EasyLinkage (v. 4.00beta)
interface operating Fastlink (v1.4) and Genehunter (v2.1r5)
algorithms assuming the disorder was dominantly transmitted,
fully penetrant and had a gene frequency of 0.001 in the
background population. Marker frequencies were derived from
the pedigree data.
Nuclear gene expression studies
Patient (III:1 and II:2) and control primary fibroblasts were
cultured in DMEM containing 4.5 g/l glucose and 0.58 g/l
L-glutamine (Sigma) supplemented with 10% FBS (Gibco) and
maintained in humidified incubator at +37C with 5% CO2. Cells
were cultured to reach 90% confluency in fresh medium, and
collected using 0.25% Trypsin (Invitrogen). Total cellular RNA
was extracted utilizing RNeasy mini kit (QIAgen). cDNA synthesis
was performed with 500 ng of total RNA, 0.25mg of random
primers, 300 mM dNTPs, 25U of RNasin ribonuclease inhibitor
and 200U of M-MLV reverse transcriptase in 40 ml of its buffer
(Promega). Measurements of transcript levels were performed
with quantitative PCR application, utilizing Applied Biosystem
(ABI PRISM 7000 Sequence Detection System). The assay-
on-demand primers were as follows: Twinkle (Hs00222440_m1),
Ant 1 (Hs00154037_m1) and b-actin (Hs00181698_m1). Primers
were cDNA specific, not amplifying genomic DNA. PCR reactions
were made using 1 ml of cDNA, 1.5 ml assay mix and 15 ml TaqMan
Universal PCR Master Mix (Applied Biosystem) in total volume of
30 ml. Every sample was analysed as duplicates or triplicates.
Results were analysed with the aid of 7000 SDS 1.2 Sequence
Detection Software (Applied Biosystems).
Results
Muscle histochemistry and biochemistry
Muscle biopsy of the index case (II:5) revealed features that
were diagnostic of mitochondrial myopathy. Approximately
10% of all fibres were deficient in histochemical COX
activity, with several fibres showing evidence of subsarco-
lemmal accumulation of abnormal mitochondria (2%
ragged-red fibres, Fig. 2a). Similar findings were apparent
in the biopsy from her sister (Patient II:2), whereas the
histochemical COX defect in Patient III:1 was less
pronounced with only 2% COX-deficient cells with no
ragged-red fibres.
Biochemical investigation of respiratory chain activities
in muscle homogenates did not show any obvious defect in
complex IV activity, although there was some suggestion
that complex I activity was subtly decreased in both Patient
II:5 and Patient III:1 to 45% and 65% of controls,
respectively (Table 1).
mtDNA analysis
Total muscle DNA was analysed for possible mtDNA
rearrangements by Southern blotting, long-range PCR and
real-time PCR. Southern blotting of total muscle DNA
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Fig. 2 Histochemical and molecular genetic analysis of muscle biopsy. (a) Histochemical demonstration of combined COX and SDH
activities in muscle biopsy from Patient II:5, revealing 10% COX-deficient fibres, some showing subsarcolemmal accumulation of abnormal
mitochondria. (b) Southern blot and (c) long-range PCR analysis of muscle DNA demonstrating multiple mtDNA deletions in Patient’s II:5
muscle biopsy. (d) Long-range PCR of muscle DNA from another affected family member (Patient III:1) also reveals detectable,
multiple mtDNA deletions but to a lesser extent than observed Patient II:5. (e) Single-fibre, real-time PCR showing the low levels of
MTND4 gene deletion in individual COX-positive fibres whilst the majority of COX-deficient fibres contain high levels of mtDNA deletion,
confirming the diagnosis of a multiple mtDNA deletion disorder.
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revealed a characteristic laddering of smaller, deleted
mtDNA molecules following PvuII digestion, suggestive of
multiple mtDNA deletions (Fig. 2b). This was confirmed by
long-range PCR across the major arc region (Fig. 2c),
although the defect was less pronounced in muscle from
Patient III:1 (Fig. 2d). Real-time PCR of individual COX-
deficient and COX-positive muscle fibres showed high
levels of deleted mtDNA in the majority, but not all, of the
COX-deficient fibres (Fig. 2e), a pattern typical in patients
with multiple mtDNA deletion disorders (He et al., 2002).
Sequencing of the entire mtDNA coding region in muscle
from Patient II:5 revealed a number of known polymorphic
variants and a previously unreported change (m.8839G4A)
in the MTATP6 gene. Hot-last cycle PCR–RFLP analysis
demonstrated heteroplasmy at this site in muscle from this
patient (39% mutated mtDNA in muscle) and Patient II:2
(81% mutated mtDNA in muscle), and also showed that
the m.8839G4A mutation was present at higher levels in
post-mitotic tissues than circulating lymphocytes (2% in
Patient II:5, 2% in Patient III-6 and 6% in II:3), a common
trait of pathogenic mtDNA point mutations (Fig. 3a).
Single-fibre PCR–RFLP analysis of COX-positive and COX-
deficient fibres from both Patients II:2 and II:5 did not
however demonstrate any segregation of the mutant
genotype with the histochemical defect, inferring that
although heteroplasmic, this sequence variant was a
polymorphism (Fig. 3b and c).
Nuclear genetic analysis
No sequence variants were identified in the coding region
or flanking exon–intron boundaries for POLG1, PEO1,
POLG2 and SLC25A4. The expected maximum LOD score
at zero recombination () for the dominant model was
2.06 (SD= 0.79). Microsatellite analysis excluded linkage to
POLG1 and PEO1. (Supplementary Figs 1a and b, and
Supplementary Tables 1 and 2). Positive LOD scores were
obtained for the region of chromosome 4 including
SLC25A4 (Zmax= 2.11 at y= 0, Supplementary Fig. 1c,
Supplementary Table 3). All affected subjects and one
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Fig. 3 Analysis of m.8839G4A MTATP6 substitution. (a) Quantification of the relative amounts of mutant and wild-type mtDNA in avail-
able patient samples by hot-last cycle PCR^RFLP analysis. Lane 1, uncut sample; lanes 2 and 7, control DNA; lane 3, skeletal muscle DNA
(Patient II:5); lane 4, blood (Patient II:5); lane 5, blood (Patient III:6); lane 6, blood (II:3). The proportion of mutant mtDNA (%) is shown
beneath each lane. (b) Single-fibre PCR^RFLP analysis of the mutation in individual skeletal muscle (COX-positive and COX-
deficient) fibres. (d) Graphical representation of the data presented in (b) confirming a lack of segregation of high levels of the m.8839G4A
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Table 1 Activities of the mitochondrial respiratory chain
complexes in patient muscle
II:5 III:1 Controls (n=20)
Complex I 0.072 0.104 0.166 0.047
Complex II 0.137 0.281 0.208 0.070
Complex IV 2.600 1.147 1.805 0.550
All respiratory chain activities are expressed relative to the activ-
ity of the mitochondrial matrix marker, citrate synthase. Complex
I is expressed as nmols NADH oxidized min1 unit citrate
synthase1.Complex II is expressed as nmols DCPIP reducedmin1
unit citrate synthase1. Complex IV is expressed as Ks1 unit
citrate synthase1103.
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unaffected individual (II:4) shared all chromosome 4
marker alleles apart from the 4p telomeric marker
D4S425 (Supplementary Fig. 2).
The expression levels of Twinkle and Ant 1 were
normalized against a ubiquitously expressed housekeeping
gene, b-actin. The expression levels of Twinkle (PEO1)
showed to be similar in all the cell lines. The expression
level of Ant 1 in the cells of Patient II:2 was similar
compared to control, whereas the cells of Patient III:1
showed increased expression up to 2-fold compared to
control (Supplementary Fig. 3). This is unlikely to have any
affect on the phenotype and is considered as normal
variation.
Sequence analysis revealed a heterozygous mis-sense
mutation in exon 17 of OPA1: c.1635C4G, predicted to
alter the amino acid sequence (p.S545R, Fig. 4a). The
mutation was present in all eight affected individuals, and
not in three unaffected individuals, nor 280 British control
chromosomes.
Discussion
Affected individuals in the family described here initially
presented with bilateral visual failure and optic atrophy of
childhood onset, followed by hearing impairment, ophthal-
moplegia, and a combination of cerebellar and sensory
ataxia in adulthood, partly related to the sensory-motor
neuropathy. Histochemical and biochemical analysis
revealed a defect affecting respiratory chain complex I in
a muscle homogenate, and a mosaic defect of complex IV
(COX) affecting specific muscle fibres. These findings
pointed towards a defect involving mtDNA.
At the time of the initial study, IV:3 was clinically
unaffected, and the inheritance pattern was therefore
consistent with a maternally inherited mtDNA defect
(Fig. 1). After excluding common mtDNA point mutations,
we therefore sequenced the entire mitochondrial genome,
and identified a previously unreported nucleotide transition
(m.8839G4A) in MTATP6. This mutation was heteroplas-
mic, suggesting that it was of recent onset, it was present in
higher percentage levels in post-mitotic tissues than blood,
it was not present in the mtDB Human Mitochondrial
Genome Database (http:www.genpat.uu.se/mtDB/) of
42700 mtDNA sequences, and it altered a highly conserved
Alanine residue at position 105 of the ATPase6 protein to a
Threonine residue (A105T). All of these features point
towards a causative pathogenic mtDNA mutation.
However, although different mutations in MTATP6 can
cause disease, a defect in the ATP synthetase would not
explain the complex I and histochemical complex IV
deficiencies present in multiple family members, as
demonstrated by a lack of segregation of the m.8839G4A
mutation in individual COX-deficient muscle fibres. This
prompted further mtDNA analysis, which identified multi-
ple deletions of mtDNA in skeletal muscle, indicating a
generalized disorder of mtDNA maintenance.
The heterozygous OPA1 mutation, c.1635C4G
(p.S545R), segregated with the disease phenotype in six
patients, is predicted to alter a highly conserved neutral
amino acid residue to an acidic residue in the GTPase
domain of the protein (Fig. 4b). Although the OPA1 base
substitution is novel, a mutation affecting the same codon
resulting in the same amino acid substitution has previously
been described in three members of a Japanese family
affected with ad-OA (Nakamura et al., 2006). Moreover, the
Japanese substitution was not detected in 100 Japanese
(Nakamura et al., 2006), and c.1635C4G was not detected
in 140 British controls. Given that linkage, mutation and
expression analysis effectively excluded a coding or
promoter region mutation of POLG1, POLG2, PEO1 or
SLC25A4, we conclude that the clinical phenotype affecting
this family is due to the c.1635C4G (p.S545R) OPA1
mutation. Further evidence to support this is offered by the
finding of the same mutation in a French patient who
presented with bilateral optic atrophy, an axonal sensory-
motor neuropathy and gait ataxia whose muscle biopsy
reveals COX-deficient fibres and multiple mtDNA deletions
(Patrizia Amati-Bonneau and Valerio Carelli, manuscript
submitted).
Dominant optic atrophy, ptosis, ophthalmoplegia and
sensorineural deafness has previously been described in a
Belgian and North American family with the p.R445H
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Fig. 4 Heterozygous OPA1mutation c.1635C4A (p.S545R). (a) Sequence chromatogram, arrow indicates mutation. (b) Amino acid sequence
conservation in the opa1 protein flanking the mutation.
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OPA1 GTPase-domain mutation (Payne et al., 2004;
Li et al., 2005). Intriguingly, p.R445H is one of the most
common OPA1 mutations, but the phenotype usually only
involves the visual system (eOPA1 database). It remains to
be established why the same mutation can cause an organ-
specific phenotype in some families, but a multi-system
disorder in another. The family we describe here provide a
clue as to the underlying disease mechanism, with broader
implications for the pathophysiology of ad-OA caused by
mutations in OPA1.
The opa1 protein is a 960 amino acid mitochondrial
dynamin-related GTPase involved in the regulation of
mitochondrial fusion (Delettre et al., 2000; Olichon et al.,
2002). Downregulation of opa1 leads to inner mitochon-
drial membrane disruption, fragmentation of mitochondria
and an increased propensity for apoptosis (Olichon et al.,
2002; Olichon et al., 2003; Olichon et al., 2007), but the
precise function of opa1 is not known, and it is not clear
how mutated opa1 causes respiratory chain dysfunction.
There is emerging evidence that mitochondrial morphology
is intimately linked to oxidative phosphorylation and the
maintenance of mtDNA. Proteolytic processing of opa1 in
patients with mitochondrial encephalopathies leads to
mitochondrial fragmentation (Duvezin-Caubet et al.,
2006), and depletion of mtDNA has been documented in
peripheral blood leucocytes from patients with OPA1
mutations (Kim et al., 2004). Our observation of age-
associated somatic multiple mtDNA deletions in the skeletal
muscle of patients with an OPA1 mutation demonstrates
the importance of opa1 in maintaining the structural
integrity of mtDNA. Given that both opa1 and mtDNA are
intimately related to the inner mitochondrial membrane
(Olichon et al., 2002), opa1 could be a component of the
mtDNA nucleoid, which is the structural and functional
unit of mtDNA expression and segregation within the cell
(Garrido et al., 2003). It is likely that disruption of the
nucleiod would lead to enhanced mtDNA mutation, and
facilitate the clonal expansion of somatic mtDNA mutations
(Jacobs et al., 2000). Neurons and skeletal muscle are
particularly vulnerable to the accumulation of somatic
mtDNA mutations (Corral-Debrinski et al., 1992;
Cortopassi et al., 1992a; Cortopassi et al., 1992b), and
any process that accelerates mutation and/or clonal
expansion will preferentially affect these tissues. This
would explain why the family we describe here have a
classical ‘mitochondrial’ phenotype with PEO and ataxia.
A milder disruption of the same process would also explain
why the extra-ocular muscle bears the brunt of the
pathology in ad-PEO. Pre-myelinated retinal ganglion cells
are rich in mitochondria (Andrews et al., 1999), making
them particularly vulnerable to subtle perturbations of
mitochondrial function, as in Leber hereditary optic
neuropathy (Carelli et al., 2004).
Why did we also find the novel m.8839G4A MTATP6
mtDNA mutation in this family? Heteroplasmy implies a
recent mutation event. This could simply be a co-incidence,
but given that this substitution has never been seen in 2600
controls, this seems unlikely. The mutation could be a
consequence of the enhanced mtDNA mutation rate in
subjects with the c.1635C4G (p.S545R) mutation in OPA1.
Mutation in the female germ-line followed by random
genetic drift through the mtDNA bottleneck could lead to
high levels within this pedigree. Although m.8839G4A does
not appear to be the primary cause of the mitochondrial
disorder affecting this family, it has the potential to impair
ATP synthesis, and thus modify the clinical phenotype. It
was present at low levels in blood of both clinically affected
and unaffected maternal relative, and was present at higher
levels in skeletal muscle of one individual, implying that the
mutation segregates to high levels in other post-mitotic
tissues such as optic nerve.
Two animal models of ad-OA have recently been
described: one with a splice site mutation in OPA1 leading
to a loss of the GTPase domain (Alavi et al., 2007), and the
other with a premature stop codon mutation in OPA1
immediately before the central dynamin GTPase (Davies
et al., 2007). Both models mimic the human disease, with
progressive visual failure due to the focal neurodegenera-
tion of retinal ganglion cells in the papilomacular bundle.
In both models, homozygous mutation are embryonic
lethal, demonstrating the fundamental importance of opa1
for human development. These mice will be invaluable in
elucidating the underlying disease mechanisms in ad-OA,
and provide an ideal tool to study the accumulation of
somatic mtDNA mutations in a range of neural and non-
neural tissues. In this way we will test the hypothesis that
the phenotype is related to, or is modulated by, clonally
expanded mtDNA mutations.
Our observations have broader implications for other
proteins involved in mitochondrial fusion and fission. Like
opa 1, mitofusin (mfn) 1 and 2 are pro-fusion dynamin-
related GTPases whose function is balanced by the pro-
fission GTPases (Drp1) and Fis1 (Lee et al., 2004; Chen
et al., 2005). Mutations in MFN2 are a common cause of
CMT2A (Zuchner et al., 2004), occasionally with optic
atrophy and deafness (Verhoeven et al., 2006; Zuchner
et al., 2006), and recently a mutation in DRP1 have been
described in a childhood encephalopathy with lactic
acidosis (Waterham et al., 2007). Given the emerging
relationship between mitochondrial structure and mtDNA
integrity, it is possible that a disruption of mtDNA
maintenance is central to the pathophysiology of these
disorders. It is intriguing that a major disruption of
mitochondrial morphology occurs in cells lacking Fis1,
leading to phenotypic changes reminiscent of cellular
senescence (Lee et al., 2007). Again, somatic mutation of
mtDNA may be involved here, possibly contributing to age-
related neurodegeneration (Sorensen et al., 2001; Bender
et al., 2006).
In conclusion, we have shown that mutation of OPA1 is
linked to the formation of multiple somatic mtDNA
deletions, and that these contribute to the phenotype.
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It is likely that OPA1 is a gene important for mtDNA
maintenance, which should be considered in patients with
unexplained multiple mtDNA deletions.
Supplementary material
Supplementary material is available at Brain online.
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